CEO & Head of Investor Relations
Martin Åmark holds a M Sc. in industrial engineering and management from Linköping Institute of Technology and a MBA from INSEAD. He has 8 years of experience from Bain & Co as a management consultant. At Bain Martin worked mainly with M&A, strategy and organisation with Nordic clients across multiple industries, including life science and pharmaceuticals.
COO & Head of Biosimilars
Siavash Bashiri holds a M Sc. in Molecular Biotechnology from Uppsala University. His latest position was with Agilent Technologies where he was the head of sales in EMEA for one of Agilent Technologies’ products within the Genomics department. He also has great knowledge of the commercialization of biotech start-ups from previous experiences.
Susanna Helgesen holds a M Sc. in Business Administration and Finance from Stockholm University. She has a background in the Finance industry and worked 4 years as equity research analyst at Remium Nordic. She has also many years’ experience from the energy and raw materials sector and her latest position was as CFO at Dome Energy.
Dr. Paolo Sarmientos
Head of Long-term injectables
Paolo Sarmientos has a Ph.D in bio-organic chemistry from the University of Naples. He has more than 25 years of experience from leading positions in biopharmaceuticals for Pfizer, Genetica and Menarini. Last 15 years Paolo has served as CEO of Primm and successfully built up a service business focused on pharmaceutical industries as well as pioneering technology for production of biopharmaceuticals with slow release formulation based on microspheres.
Dr. David Vikström
David Vikström is the CTO of Xbrane Bioscience. He has a Ph.D. in expression and targeting of proteins in E. coli. He joined Xbrane in 2010 and successfully developed new technologies and strains for vaccine candidates. He is currently heading the development of Xbrane’s new expression systems to be able to take the expression in E. coli to new levels.